H2 2016 Androgenic Alopecia Therapeutics Review Featuring Drug Profiles, Latest Dormant Projects, Product Development, News & Press Releases
Androgenic Alopecia Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Androgenic Alopecia therapeutics industry report provides comprehensive information on the therapeutics under development for Androgenic Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history...
View full press release